非荷爾蒙避孕藥市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球非荷爾蒙避孕藥市場規模達199億美元，預計到2034年將以7%的複合年成長率成長至391億美元。民眾對安全性行為的認知不斷提高，加上政府的支持性措施以及消費者明顯轉向無荷爾蒙避孕方案，這些因素持續推動市場擴張。越來越多的消費者正在尋求能夠避免荷爾蒙避孕方法常見副作用的避孕方法。

人們對避孕套等便捷易用的避孕用品日益成長的偏好，對市場動態產生了積極影響。由於價格實惠、供應充足，以及能夠有效預防懷孕和性傳染病，發展中地區男性對保險套的需求強勁。由於情緒波動和體重增加等副作用，許多使用者正在逐漸放棄荷爾蒙避孕產品，這促使人們對更安全的替代品的需求日益成長。此外，透過多種零售和數位管道廣泛提供產品，也提升了消費者的可近性。產品可透過線上平台、連鎖藥局和附近的零售店便捷購買，從而鼓勵消費者持續使用。這些因素預計將在未來幾年保持成長勢頭。

預計器械細分市場將達到7.2%的複合年成長率，到2034年達到294億美元。此細分市場的主要產品包括子宮內避孕器 (IUD)、皮下植入物、陰道環和保險套。其中，銅子宮內避孕器因其有效性和無激素特性而廣受歡迎。保險套因其可及性和額外的抗感染保護作用，仍然是必不可少的避孕方法，使其成為非荷爾蒙避孕領域的主導產品。

2024年，女性用戶群規模達126億美元。女性持續選擇非荷爾蒙避孕方案，包括長效可逆避孕藥 (LARC)、殺精產品、植入物以及輸卵管切除術等外科手術。選擇通常受便利性、健康因素和長期可靠性的影響。輸卵管結紮術是一種永久性絕育手術，涉及輸卵管閉合，是40歲以上接近更年期的女性尋求可靠避孕方法的常見選擇。可支配收入的增加、女性就業率的提高以及生殖健康意識的增強，也促進了非荷爾蒙避孕方案的採用率。

2024年，美國非荷爾蒙避孕藥市場規模達58億美元。患有多囊性卵巢綜合症或甲狀腺疾病等荷爾蒙疾病的患者通常依賴非荷爾蒙避孕藥。不同的文化和法律對墮胎的限制進一步推動了市場的成長，促使人們更多地使用避孕措施。絕育技術的進步，包括針對男性和女性的微創技術，正在改善患者的體驗和接受度。此外，業內人士正致力於開發下一代男性避孕解決方案，包括基於注射水凝膠的避孕方法，預計這將推動未來的需求成長。

全球非荷爾蒙避孕藥市場的主要公司包括：拜耳、利潔時、邁耶、HLL Lifecare、PREGNA INTERNATIONAL、富士乳膠、Mankind、CooperCompanies、Church & Dwight Co.、SMB、CUPID、岡本、abbVie 和 VIATRIS。為了鞏固其在非荷爾蒙避孕藥領域的立足點，領先的公司優先考慮產品設計創新、拓展分銷管道並開展有針對性的宣傳活動。許多公司正在開發先進的屏障裝置和消毒工具，以提供更舒適、更有效率和更便利的使用體驗。公司投資於以使用者為中心的教育，以打破文化禁忌並促進知情選擇。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 人們對荷爾蒙避孕藥副作用的擔憂日益增加
    • 計劃延後懷孕的傾向日益增強
    • 發展中經濟體未滿足的避孕需求很高
    • 性傳染病（STD）的盛行率不斷上升
    • 政府措施提高民眾對男性絕育的認知
  • 產業陷阱與挑戰
    • 替代方法的可用性
    • 輸精管切除手術相關風險
• 成長潛力分析
• 監管格局
• 創新與永續性
  • 非荷爾蒙避孕技術創新
  • 永續發展措施與環保產品
• 報銷場景
• 差距分析
• 定價分析
• 保險套和子宮內避孕器－2024年全球和區域銷售分析
• 設備分銷前景
• 消費者行為分析
• 波特的分析
• PESTEL分析
• 價值鏈分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按類型，2021 - 2034 年

• 主要趨勢
• 裝置
  • 保險套
    • 男性
    • 女性
  • 子宮內避孕器
  • 陰道環
  • 皮下植入物
  • 其他設備
• 消毒
  • 輸精管切除術
    • 無刀輸精管切除術
    • 傳統輸精管切除術
    • 微創輸精管切除術
  • 輸卵管結紮
    • 腹腔鏡輸卵管結紮術
    • 子宮腔鏡輸卵管結紮術
    • 小切口開腹手術
    • 其他程式
• 其他產品類型

第6章：市場估計與預測：依性別，2021 - 2034 年

• 主要趨勢
• 男性
• 女性

第7章：市場估計與預測：按年齡層，2021 - 2034 年

• 主要趨勢
• 15-44歲
• 44歲以上

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• abbVie
• Bayer
• Church & Dwight Co.
• CooperCompanies
• CUPID
• FUJI LATEX
• HLL Lifecare
• Mankind
• MAYER
• VIATRIS
• Okamoto
• PREGNA INTERNATIONAL
• reckitt
• SMB
• veru

The Global Non-Hormonal Contraceptives Market was valued at USD 19.9 billion in 2024 and is estimated to grow at a CAGR of 7% to reach USD 39.1 billion by 2034. Rising public awareness around safe sexual practices, combined with supportive government initiatives and a noticeable shift toward hormone-free contraceptive solutions, continues to drive market expansion. A growing number of consumers are seeking birth control options that avoid the side effects commonly linked with hormonal methods.

An increasing preference for accessible and easy-to-use contraceptives like condoms has positively impacted market dynamics. The market had a strong uptake among men in developing regions due to affordability, availability, and dual protection against pregnancy and STDs. Many users are moving away from hormone-based options due to side effects such as mood fluctuations and weight gain, contributing to the growing demand for safer alternatives. Additionally, wide product availability through multiple retail and digital channels enhances consumer access. Products are conveniently offered via online platforms, drugstore chains, and nearby retail outlets, encouraging consistent adoption. These factors are collectively expected to sustain growth in the coming years.

The devices segment is projected to achieve a CAGR of 7.2%, reaching USD 29.4 billion by 2034. Key products in this segment include intrauterine devices (IUDs), subdermal implants, vaginal rings, and condoms. Among these, copper IUDs have become widely preferred due to their effectiveness and hormone-free nature. Condoms remain an essential method due to their accessibility and added protection against infections, making them a dominant player in the non-hormonal contraceptives space.

In 2024, the female user segment accounted for USD 12.6 billion. Women continue to opt for non-hormonal solutions including long-acting reversible contraceptives (LARCs), spermicidal products, implants, and surgical procedures like tubectomy. Choices are often influenced by convenience, health factors, and long-term reliability. Tubal ligation, a permanent sterilization procedure involving the closure of fallopian tubes, is commonly selected by women over 40 who seek a dependable birth control method as they approach menopause. Rising disposable income, increased participation of women in the workforce, and greater reproductive health awareness are also contributing to higher adoption.

U.S. Non-Hormonal Contraceptives Market was valued at USD 5.8 billion in 2024. Individuals managing hormonal conditions such as polycystic ovary syndrome or thyroid disorders often rely on non-hormonal options. Market growth is further supported by varying cultural and legal restrictions on abortion, prompting greater use of contraception. Technological advances in sterilization, including minimally invasive options for both men and women, are improving patient experience and acceptance. Additionally, industry players are focusing on developing next-generation solutions for male contraception, including injectable hydrogel-based methods, which is expected to boost future demand.

Key companies in the Global Non-Hormonal Contraceptives Market include: Bayer, Reckitt, MAYER, HLL Lifecare, PREGNA INTERNATIONAL, FUJI LATEX, Mankind, CooperCompanies, Church & Dwight Co., SMB, CUPID, Okamoto, abbVie, and VIATRIS. To strengthen their foothold in the non-hormonal contraceptives sector, leading companies prioritize innovation in product design, expand distribution channels, and launch targeted awareness campaigns. Many are developing advanced barrier devices and sterilization tools that offer greater comfort, efficiency, and accessibility. Companies invest in user-centric education to break cultural taboos and promote informed choices.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising concerns over side effects of hormonal contraceptives
    • 3.2.1.2 Growing inclination towards planned delayed pregnancy
    • 3.2.1.3 High unmet contraceptive needs in developing economies
    • 3.2.1.4 Growing prevalence of sexually transmitted diseases (STD)
    • 3.2.1.5 Government initiatives raising awareness about male sterilization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative methods
    • 3.2.2.2 Risk associated with vasectomy surgeries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Innovation and sustainability
  • 3.5.1 Technological innovations in non-hormonal contraceptives
  • 3.5.2 Sustainability initiatives and eco-friendly products
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Pricing analysis
• 3.9 Condoms and IUDs - global and regional volume analysis, 2024
• 3.10 Distribution outlook for devices
• 3.11 Consumer behavior analysis
• 3.12 Porter's analysis
• 3.13 PESTEL analysis
• 3.14 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Condoms
    • 5.2.1.1 Male
    • 5.2.1.2 Female
  • 5.2.2 Intra-uterine devices
  • 5.2.3 Vaginal rings
  • 5.2.4 Subdermal implants
  • 5.2.5 Other devices
• 5.3 Sterilization
  • 5.3.1 Vasectomy
    • 5.3.1.1 No-scalpel vasectomy
    • 5.3.1.2 Conventional vasectomy
    • 5.3.1.3 Minimally invasive vasectomy
  • 5.3.2 Tubal ligation
    • 5.3.2.1 Laparoscopic tubal ligation
    • 5.3.2.2 Hysteroscopic tubal ligation
    • 5.3.2.3 Mini-Laparotomy
    • 5.3.2.4 Other procedures
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 15-44 years
• 7.3 Above 44 years

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 abbVie
• 9.2 Bayer
• 9.3 Church & Dwight Co.
• 9.4 CooperCompanies
• 9.5 CUPID
• 9.6 FUJI LATEX
• 9.7 HLL Lifecare
• 9.8 Mankind
• 9.9 MAYER
• 9.10 VIATRIS
• 9.11 Okamoto
• 9.12 PREGNA INTERNATIONAL
• 9.13 reckitt
• 9.14 SMB
• 9.15 veru